Baker McKenzie advised CureVac N.V. (Nasdaq: CVAC) on a EUR 150 million collaboration with GlaxoSmithKline plc (LSE/NYSE: GSK), building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine. GSK will also support the manufacture of up to 100 million doses of CureVac’s first generation COVID-19 vaccine candidate CVnCoV in 2021.
Through this new exclusive co-development agreement, GSK and CureVac will contribute resources and expertise to research, develop, and manufacture a number of novel mRNA vaccine candidates, including multi-valent and monovalent approaches. The aim of this work is to offer broader protection against a variety of different SARS-CoV2 variants, and to enable a quick response to new variants potentially emerging in the future. The development programme will begin immediately, with the target of introducing the vaccine in 2022, subject to regulatory approval.
"Once again, we were able to assist CureVac on an important collaboration agreement with GSK that can build on an existing relationship between the two companies to jointly develop next generation mRNA-based vaccines. With the help of GSK’s proven vaccine expertise, our client is equipping itself to tackle future health challenges with novel vaccines", comments Dr. Constanze Ulmer-Eilfort, lead partner on the transaction at Baker McKenzie.
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, the company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. It is headquartered in Tübingen, Germany, and employs more than 500 people at its sites in Tübingen, Frankfurt, and Boston, USA.
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.
CureVac is a long-standing client of Baker McKenzie. Under the leadership of Dr. Constanze Ulmer-Eilfort, Baker McKenzie advised CureVac, inter alia, on a vaccine alliance with Bayer AG (January 2021), on a strategic collaboration agreement with GlaxoSmithKline (GSK) for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens, on the strategic partnership with Genmab A/S for the development of mRNA-based antibody therapeutics, on a collaboration and license agreement with Eli Lilly and Company, on a collaboration and license agreement with Boehringer Ingelheim, as well as on cooperation agreements with the international vaccine alliance CEPI and the Bill & Melinda Gates Foundation.
Legal advisor to CureVac N.V.:
Lead: IP: Dr. Constanze Ulmer-Eilfort (partner, Munich)
Team: IP: Julia Schieber (senior associate, Zurich)